CYCLACEL PHARMACEUTICALS INC (CYCC)
US23254L8019 - Common Stock
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
Lengthens Patent Exclusivity of Plogosertib until August 2040
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
NOTICE OF INTENTION TO GRANT OF NEW EUROPEAN PATENT COVERING PLOGOSERTIB PHARMACEUTICAL COMPOSITIONS - Lengthens Patent Exclusivity to August 2040...
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS,...
CYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS for Q1 2024
CYCC stock results show that Cyclacel Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Why Is Coursera (COUR) Stock Down 16% Today?
Coursera stock is falling on Tuesday as COUR investors react to the company's lackluster guidance in its latest earnings report.
Why Is Medifast (MED) Stock Down 20% Today?
Medifast stock is down on Tuesday after the company released mixed results for Q1 2024 alongside a weak outlook for Q2 2024.
Why Is Greenwave Technology Solutions (GWAV) Stock Up 15% Today?
Greenwave Technology Solutions stock is up on Tuesday alongside heavy trading of GWAV shares despite a lack of news from the company.
Why Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?
Cyclacel Pharmaceuticals stock is up on Tuesday with heavy trading of CYCC shares after the company withdrew a public offering.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Our coverage for Tuesday starts with a dive into the biggest pre-market stock movers traders will want to keep an eye on today!
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
BERKELEY HEIGHTS, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid...